SIBN

Si-Bone (SIBN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript

SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building on momentum across its sacroiliac joint, complex spinal fusion and trauma offerings, while preparing for a broader launch of its newly cleared iFuse Granite Onyx platform.

Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representing growth of 14.5%   U.S. revenue of $52.8 million, representing growth of 13.9% Gross margin of 79.3%   Net loss of $3.6 million, representing an improvement of 20.7%   Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4% Positive cash from operations of $5.9 million, representing an improvement of 154.4% $146.3 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) 1,770 active U.S. physicians, representing growth of ~16%       In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.

Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.